僅用于工業(yè)應(yīng)用或科學(xué)研究，不可用于人類或動(dòng)物的臨床診斷或治療，非藥用.Eculizumab （Anti-Complement C5） is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex （MAC）. Eculizumab has the potential for haemolysis research. Eculizumab （Anti-Human C5, Humanized Antibody） 是一種針對(duì)補(bǔ)體 C5 （complement C5） 的長(zhǎng)效人源化單克隆抗體。Eculizumab 抑制 C5 裂解為 C5a 和 C5b，因此抑制末端補(bǔ)體系統(tǒng)的部署，包括膜攻擊復(fù)合物 （MAC） 的形成。Eculizumab 具有用于溶血研究的潛力